icon3

Schizophrenia Drugs Market: By Treatment Type (Oral, Injectables) By Therapeutic Class (First-Generation Antipsychotics, Second-Generation Antipsychotics, Third-Generation Antipsychotics) Regional Analysis & Forecast - 2026

  • OI-156
  • |
  • Published date: Jul, 2019
  • |
  • Central Nervous System Diseases
  • |
  • 145 Pages

Introduction

Schizophrenia is a chronic and disabling brain disorder. People with schizophrenia may hear voices other people don’t hear or have a false belief that others are plotting to harm them. As with most illnesses, schizophrenia symptoms can range from mild to severe and can cause fearfulness, withdrawal, or extreme agitation. There are now reliable tools for diagnosing schizophrenia, as well as effective medical therapies that can reduce hallucinations and delusions which is driving the market growth. The overall Global Schizophrenia Drugs market was valued at $ 6.84 bn in 2018 and is forecasted to grow at a strong 2.79% CAGR between 2018 and 2026, resulting in 2026 global sales of $ 8.30 bn. However, the increase in cases of addiction-related to these drugs is restraining the market growth. Moreover, using advanced tools and methods for disease genetics are provide ample opportunities for the market.


Schizophrenia Drugs depending on Therapeutic Class, Second-generation antipsychotics (SGAs) segment is expected to account for the largest share of the Schizophrenia Drugs market due to Second-generation antipsychotics (SGAs), beginning with clozapine, were introduced as having equal or better efficacy, particularly with negative symptoms, and lower risk of extrapyramidal symptoms and tardive dyskinesia.


Key Developments


  • On July 22, 2019: BioXcel Therapeutics product candidate BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia


Segmentation

The Global Schizophrenia Drugs Market is segmented on the basis of Type, Therapeutic Class, and Region

Based on the Type: Injectables and Oral

Based on Therapeutic Class: Third-Generation Antipsychotics, Second-Generation Antipsychotics, and First-Generation Antipsychotics


Based on the Region: North America, Asia-Pacific, Europe, and LAMEA. Among that the Asia Pacific held the largest share of the market due to a significant segment of the populace is moving toward such prescription treatments, basically because of frenzied lifestyles. Besides, the nation offers very propelled therapeutic consideration, for early treatment abilities, alongside the contribution of government in expanding human services use


The key players of the Global Schizophrenia Drugs Market include Bristol-Myers Squibb, Eli Lilly and Company, Alkermes plc, Novartis International Ag, Teva Pharmaceutical Industries Ltd, Sanofi S.A. and etc.

 

 

 



 

 

 

Report Description: The report covers an in-depth analysis of the Global Schizophrenia Drugs Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by therapeutic class (Third-Generation Antipsychotics, Second-Generation Antipsychotics, and First-Generation Antipsychotics). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.

The report includes in-depth company profiles of key players in the Global Schizophrenia Drugs Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.

The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.

Scope:

• Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Schizophrenia Drugs Market
• Provides a comparative analysis of key marketed and pipeline products
• Provides key information on players involved in the Global Schizophrenia Drugs Market
• Provides a complete overview of market segments and the regional outlook of Global Schizophrenia Drugs Market
• Provides in-depth coverage of key news related to Global Schizophrenia Drugs Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 






  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 






  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 






  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 





REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Corporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)